OPEN ACCESS

Original research

Testing the effects of combining azithromycin with inhaled tobramycin for *P. aeruginosa* in cystic fibrosis: a randomised, controlled clinical trial

David P Nichols ,^{1,2} Pradeep K Singh,³ Arthur Baines,² Lindsay J Caverly,⁴ James F Chmiel,⁵ Ronald L Glibson,¹ Jorge Lascano,⁶ Sarah J Morgan,³ George Retsch-Bogart,⁷ Lisa Saiman,⁸ Hossein Sadeghi,⁸ Joanne L Billings,⁹ Sonya L Heltshe ,^{1,2,10} Shannon Kirby,² Ada Kong,¹¹ Jerry A Nick,^{12,13} Nicole Mayer-Hamblett,^{1,2,10} TEACH Study Group

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2021-217782>).

For numbered affiliations see end of article.

Correspondence to

Dr David P Nichols, Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA; David.Nichols@seattlechildrens.org

JAN and NM-H contributed equally.

JAN and NM-H are joint senior authors.

Received 11 June 2021
Accepted 30 September 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Nichols DP, Singh PK, Baines A, et al. *Thorax* Epub ahead of print: [please include Day Month Year]. doi:10.1136/thoraxjnl-2021-217782

ABSTRACT

Rationale Inhaled tobramycin and oral azithromycin are common chronic therapies in people with cystic fibrosis and *Pseudomonas aeruginosa* airway infection. Some studies have shown that azithromycin can reduce the ability of tobramycin to kill *P. aeruginosa*. This trial was done to test the effects of combining azithromycin with inhaled tobramycin on clinical and microbiological outcomes in people already using inhaled tobramycin. We theorised that those randomised to placebo (no azithromycin) would have greater improvement in forced expiratory volume in one second (FEV₁) and greater reduction in *P. aeruginosa* sputum in response to tobramycin.

Methods A 6-week prospective, randomised, placebo-controlled, double-blind trial testing oral azithromycin versus placebo combined with clinically prescribed inhaled tobramycin in individuals with cystic fibrosis and *P. aeruginosa* airway infection.

Results Over a 6-week period, including 4 weeks of inhaled tobramycin, the relative change in FEV₁ did not statistically significantly differ between groups (azithromycin (n=56) minus placebo (n=52) difference: 3.44%; 95% CI: -0.48 to 7.35; p=0.085). Differences in secondary clinical outcomes, including patient-reported symptom scores, weight and need for additional antibiotics, did not significantly differ. Among the 29 azithromycin and 35 placebo participants providing paired sputum samples, the 6-week change in *P. aeruginosa* density differed in favour of the placebo group (difference: 0.75 log₁₀ CFU/mL; 95% CI: 0.03 to 1.47; p=0.043).

Conclusions Despite having greater reduction in *P. aeruginosa* density in participants able to provide sputum samples, participants randomised to placebo with inhaled tobramycin did not experience significantly greater improvements in lung function or other clinical outcomes compared with those randomised to azithromycin with tobramycin.

BACKGROUND

Two of the earliest pulmonary drug therapies proven effective for people with cystic fibrosis (PwCF) are inhaled tobramycin and oral azithromycin.^{1,2} The CF National Patient Registry in the USA reports

Key messages

What is the key question?

- This trial tested whether or not using azithromycin diminished the short-term clinical or microbiological effects of ongoing inhaled tobramycin in people with cystic fibrosis.

What is the bottom line?

- Despite a greater reduction in sputum density of *Pseudomonas aeruginosa*, people treated with placebo compared with azithromycin did not have greater improvement in lung function or disease-related quality of life during treatment with inhaled tobramycin.

Why read on?

- This is one of the few trials to consider the impact of approved drugs in combination in CF and provides some reassurance for a common clinical practice pattern while identifying the need to better understand long-term effects of chronic therapies and the clinical relevance of microbiological changes in the airway.

that these two antibiotics are used in approximately two-thirds of PwCF who have persistent *Pseudomonas aeruginosa* airway infection, and the majority use them in combination.³ However, our prior in vitro and murine model studies found that azithromycin potentially reduced the antibacterial effect of tobramycin against *P. aeruginosa*.⁴⁻⁶ Moreover, post-hoc analyses of clinical and research databases indicated that individuals on chronic oral azithromycin may benefit less from inhaled or intravenous tobramycin when compared with those not using this macrolide therapy.⁴⁻¹⁰ Given the widespread concomitant use of both drugs and desire to not rely on in vitro or post-hoc analyses, a prospective, randomised, placebo-controlled clinical trial was conducted to test if the absence of concomitant azithromycin improved the clinical benefits and *P. aeruginosa* killing expected from inhaled tobramycin (NCT02677701). The primary hypothesis tested in this trial was that those randomised

Figure 1 Study design schematic. The study consisted of three visits during the 6-week randomised period. Participants were randomly allocated 1:1 to receive oral AZM (500 mg) or placebo three times per week throughout the 6-week period. Two weeks post-randomisation, participants started their usual inhaled TOB solution or powder two times per day for 4 weeks while continuing on study drug (AZM or placebo, see online supplemental material for details) to complete the 6-week study. Participants completing the study were offered optional, additional participation in an 8-week open-label period. AZM, azithromycin; TOB, tobramycin.

to receive placebo (vs azithromycin) with inhaled tobramycin would experience greater increase in lung function measured by forced expiratory volume in one second (FEV₁). Secondly, we tested the impact on other clinical outcomes and the hypothesis that those given placebo would experience greater reduction in *P. aeruginosa* sputum density. Some of the results have been presented as an abstract.¹¹

METHODS

Study design

The TEACH study was a prospective, randomised, placebo-controlled, double-blinded, clinical trial investigating the effects of oral azithromycin in combination with inhaled tobramycin on clinical and microbiological outcomes among PwCF and *P. aeruginosa* airway infection. Figure 1 displays the overall study design for the 6-week randomised study followed by an optional open-label period, the results of which will be published separately. Participants were randomised 1:1 to azithromycin 500 mg three times per week or placebo at week 0, which was followed 2 weeks later by initiation of their prescribed inhaled tobramycin for an additional 4 weeks. An adaptive algorithm was used to balance randomisation by per cent of predicted FEV₁ (ppFEV₁; 25%–50%, >50%–75% and >75%), chronic oral azithromycin use for the past 30 days (yes/no), inhaled tobramycin formulation (TIS or TIP) and site.^{12–14}

Participants were ≥12 years old with CF and otherwise clinically stable with ≥2 *P. aeruginosa* positive respiratory cultures in the last year (one of which was within the last 6 months), ppFEV₁ 25%–100% and current or prior chronic use of oral azithromycin (detailed criteria: online supplemental table E1). Participants must have used ≥2 cycles of inhaled tobramycin (4 weeks per cycle) in the 6 months prior to enrolment. The trial (NCT02677701) was conducted at 39 CF Foundation accredited care centres in the USA, was approved by central or local institutional review boards, was coordinated by the CF Therapeutics Development Network Coordinating Centre (TDNCC, Seattle, Washington, USA) and was monitored by a Data Safety Monitoring Board (DSMB) appointed by the National Heart, Lung, and Blood Institute.

Pulmonary function testing, anthropometric measures and patient-reported respiratory symptoms were collected at all study visits. Expectorated sputum collection was attempted at all

study visits for quantitative *P. aeruginosa* culture. Adherence to inhaled tobramycin and study drug were collected using participant daily diaries. Adherence to study drug was also assessed using the number of study drug capsules remaining in study drug bottles.

Study endpoints

The primary endpoint was the relative change in FEV₁ litres, from baseline (week 0) to week 6, which included the necessary 2-week period post-randomisation important for either wash-out or wash-in of azithromycin prior to the initiation of inhaled tobramycin. A key secondary endpoint was the relative change in FEV₁ litres from week 2 to week 6 when participants were taking inhaled tobramycin in addition to study drug (azithromycin vs placebo).

Additional secondary clinical endpoints included: changes in ppFEV₁ (global lung initiative reference equations¹⁵); changes in weight; need for acute intravenous, oral or inhaled antibiotics or hospitalisation during the study; and incidence of pulmonary exacerbation.^{16–17} Patient-reported secondary endpoints were changes in the Cystic Fibrosis Questionnaire–Revised: Respiratory Symptom Score (CFQ-R RSS) and the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).^{18–19}

The key microbiological endpoint, an additional secondary endpoint, was change in *P. aeruginosa* sputum density from baseline to week 6. The change from week 2 to week 6 (inhaled tobramycin use) was also determined. Sputum samples were immediately processed and frozen at study sites before being shipped to a blinded, centralised microbiology laboratory (see online supplemental file). Safety endpoints included rates of adverse events (AEs), including QTc >500 ms or increase in QTc of ≥60 ms.

Statistical analysis

Analyses were performed on the modified intent-to-treat (m-ITT) population, defined as all randomised participants who received more than one dose of study drug. Analysis of the primary endpoint was repeated using the per-protocol (PP) population, defined as participants in the m-ITT population who completed ≥80% of their doses of study drug, did not require use of acute antibiotics or steroids and had no major protocol violations. Analysis of the microbiology endpoint was performed on the subset of the m-ITT population from whom paired expectorated sputum samples were collected to measure change in *P. aeruginosa* density.

The primary endpoint was compared between treatment groups using a linear regression model adjusted for ppFEV₁ (25%–50%, >50%–75% and >75%), azithromycin use at baseline and tobramycin formulation (inhaled tobramycin formulation: powder (TIP) vs solution (TIS)). Continuous secondary endpoints were modelled similarly to the primary endpoint. Counts and percentages were summarised and Fisher's exact tests with corresponding 95% CIs derived from the Newcombe-Wilson method without continuity correction were used to compare treatment groups. Rate ratios were estimated using Poisson regression with an offset of the logarithm of observation time.

A two-sided, 0.05 significance level was used. With 120 participants assuming 10% attrition, the study had 85% power to detect a treatment effect of 7.5% or greater in the relative change in FEV₁ litres using an estimated SD of 13 L for FEV₁.¹² There was no alpha adjustment for multiple testing for secondary

Figure 2 Overview of the study population. Individuals screened, randomised, length of follow-up and included in the analytical populations. AZM, azithromycin; m-ITT, modified intention-to-treat; Pa, *Pseudomonas aeruginosa*; PP, per-protocol.

efficacy variables. P values from these tests were considered descriptive and evaluated for nominal significance only when $p < 0.05$. Interim monitoring for efficacy/harm was performed by the DSMB at prespecified time points after 50% and 75% of participant completion.

RESULTS

Study population

Between October 2016 and December 2019, 136 participants screened for study eligibility and 119 participants were randomised: 57 to placebo and 62 to azithromycin. Four participants did not receive study drug and were not replaced. Three were determined ineligible before their first dose and one voluntarily withdrew (figure 2).

Demographics and baseline characteristics for the 115 randomised and treated participants (ITT population) were similar between groups (table 1). The azithromycin group had slightly more heterozygous for F508del (28%) than the placebo group (20%). Mean FEV₁ was 2.59 L (SD: 0.81 L) in the azithromycin group and 2.50 L (SD: 0.85 L) in the placebo group. Chronic medication use was comparable, though more placebo participants used cystic fibrosis transmembrane conductance regulator (CFTR) modulators (69% vs 51% in the azithromycin group).

Of the 115 randomised and treated participants, 5 from the azithromycin group and 2 from the placebo group withdrew from the study early. Two additional placebo participants discontinued study drug permanently while enrolled (figure 2). Mean follow-up time was similar, averaging 6.1 weeks in the azithromycin group and 6.4 weeks in the placebo group.

Adherence to three times per week study drug self-administration (azithromycin or placebo) was 90.9% (SD: 21.3%) of expected doses in the azithromycin group and 95.8%

Table 1 Participant baseline characteristics and demographics by treatment group

Characteristics	Azithromycin (N=61)	Placebo (N=54)
Age, years	26.1±9.9	26.5±9.7
Age, n (%)		
≥12–<18 years	14 (23.0)	12 (22.2)
≥18–<30 years	28 (45.9)	25 (46.3)
≥30 years	19 (31.1)	17 (31.5)
Female, n (%)	29 (47.5)	26 (48.1)
Race, n (%)		
Caucasian	55 (90.2)	49 (90.7)
Other*	6 (9.8)	5 (9.3)
Ethnicity, n (%)		
Hispanic or Latino	9 (14.8)	7 (13.0)
FEV ₁ , L	2.59±0.81	2.50±0.85
ppFEV ₁ †	70.7±18.2	69.6±21.1
ppFEV ₁ category, n (%)		
≥25%–<50%	11 (18.0)	11 (20.4%)
≥50%–<75%	22 (36.1)	16 (29.6%)
≥75%	28 (45.9)	27 (50.0%)
Height, cm	167.9±10.2	166.4±9.6
Weight, kg	63.9±13.8	62.7±13.2
Genotype, n (%)		
F508del homozygous	38 (62.3)	35 (64.8)
F508del heterozygous	17 (27.9)	11 (20.4)
Other	6 (9.8)	7 (13.0)
Unavailable	0 (0)	1 (1.9)
Tobramycin formulation, n (%)		
Solution	33 (54.1)	28 (51.9)
Powder	28 (45.9)	26 (48.1)
History of azithromycin use, n (%)		
Current chronic user	51 (83.6)	43 (79.6)
Non-current chronic user	10 (16.4)	11 (20.4)
Chronic medication use, n (%)		
Dornase alfa	53 (86.9)	48 (88.9)
Hypertonic saline	46 (75.4)	40 (74.1)
High-dose ibuprofen	2 (3.3)	2 (3.7)
Ivacaftor	2 (3.3)	3 (5.6)
Ivacaftor/lumacaftor	14 (23.0)	18 (33.3)
Ivacaftor/tezacaftor	14 (23.0)	16 (29.6)
Elxacaftor/tezacaftor/ivacaftor	1 (1.6)	0 (0)
<i>Pseudomonas aeruginosa</i> sputum density		
Participants with sputum culture results, n (%)	38 (62.3)	39 (72.2)
<i>P. aeruginosa</i> log ₁₀ CFU/mL	4.29±1.80	4.22±1.59

Plus-minus values are mean±SD.

*Other includes Black/African American, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, unknown and other.

†Percent predicted calculated using global lung initiative reference equations.

FEV₁, forced expiratory volume in one second; ppFEV₁, percent of predicted forced expiratory volume in one second.

(SD: 15.3%) in the placebo group. Average adherence to two times per day inhaled tobramycin solution was 85.3% (SD: 21.7%) in the azithromycin group and 87.8% (SD: 17.7%) in the placebo group. Adherence for participants using tobramycin inhalation powder was 85.5% (SD: 16.5%) in the azithromycin group and 92.1% (SD: 11.8%) in the placebo group.

Figure 3 Pulmonary function outcomes: (A) mean relative (%) change from baseline in FEV₁ litres and (B) mean absolute change from baseline in ppFEV₁. Error bars are 95% CIs. AZM, azithromycin; FEV₁, forced expiratory volume in one second; ppFEV₁, forced expiratory volume in one second; TOB, tobramycin.

Pulmonary function

One hundred and eight study participants completed spirometry at both baseline and week 6 end-of-study visits, comprising the primary m-ITT population (56 azithromycin and 52 placebo). There was an average 1.69% (SD: 10.39%) relative change in FEV₁ litres at week 6 in the azithromycin group and an average -1.95% (SD: 10.73%) relative change in FEV₁ litres in the placebo group (figure 3A), which did not significantly differ between groups (mean difference adjusted for stratification factors: 3.44%; 95% CI: -0.48 to 7.35; $p=0.085$). Analysis of the primary endpoint in the PP study population was similar with a mean difference of 3.54% (95% CI: -0.82 to 7.91; $p=0.110$). Additional sensitivity analyses of the primary endpoint and individual participant data are included in online supplemental figures E1 and E2. Prespecified unadjusted subgroup analyses of the primary outcome (figure 4) were generally consistent with that of the overall study cohort across subgroups.

During the inhaled tobramycin period of the study (week 2–6), the difference between treatment groups in mean relative change in FEV₁ litres was not significant. The estimated treatment difference, adjusted for lung function at week 2, was 1.36% (95% CI: -2.55 to 5.27; $p=0.491$). The mean 6-week absolute change in ppFEV₁ was 0.6% (SD: 7.5%) and -1.9%

Figure 4 Mean relative (%) change from baseline in FEV₁ litres (unadjusted estimates) among prespecified subgroups. AZM, azithromycin; FEV₁, forced expiratory volume in one second.

(SD: 7.1%) in the azithromycin and placebo groups, respectively (figure 3B, mean difference adjusted for randomisation strata of 2.28%; 95% CI: -0.42 to 4.98; $p=0.097$). During the inhaled tobramycin portion of the study, the estimated treatment difference in ppFEV₁, adjusted for lung function at week 2, was 1.45% (95% CI: -0.94 to 3.84; $p=0.232$).

Secondary clinical outcomes

Changes in weight (kg) were similar between the two treatment groups, with a mean change from baseline to week 6 of 0.23 kg (SD: 1.44 kg) in the azithromycin group and -0.02 kg (SD: 1.40 kg) in the placebo group (online supplemental figure E3, mean difference adjusted for randomisation strata of 0.20 kg, 95% CI: -0.33 to 0.74; $p=0.454$). The proportions of participants with any antibiotic use (oral, inhaled or intravenous route), any pulmonary exacerbations and any hospitalisations during the study were comparable between the two groups (table 2).

Neither of the two patient-reported outcomes measuring respiratory symptoms showed significant differences in mean scores from baseline to week 6 (online supplemental figure E4). The CFQ-R RSS (higher score indicates fewer symptoms) had an adjusted treatment difference of 1.53 points (95% CI: -3.70 to 6.77; $p=0.563$), comparing azithromycin to placebo. The CFRSD-CRISS (lower score indicates fewer symptoms) had an adjusted treatment difference of -2.89 points (95% CI: -7.01 to 1.22; $p=0.166$). In both measures, the scores trended in favour of the azithromycin group.

Secondary microbiologic outcomes

The ability to produce sputum samples and rates of culture positivity for *P. aeruginosa* across time points varied among participants. Over 80% of sputum samples grew *P. aeruginosa* at baseline, and this was similar between the two groups. Overall, 29 of 61 (47.5%) azithromycin and 35 of 54 (64.8%) placebo participants were able to produce expectorated sputum sufficient for culture at both baseline and week 6 study visits, corresponding to 56% of the total ITT population. This subgroup was, on average, a year older and had 5.6% lower baseline ppFEV₁ than the ITT population. The azithromycin and placebo groups providing these microbiological data had similar baseline characteristics (online supplemental table E2). For comparison purposes, the difference in the 6-week relative change in FEV₁ among this subgroup (azithromycin minus placebo, unadjusted) was 5.07% (95% CI: -0.95 to 11.08) as compared with those unable to produce sputum (27 azithromycin and 17 placebo) who experienced a 2.07% difference in the relative change

Table 2 Antibiotic use, pulmonary exacerbations and hospitalisations by treatment group

	Azithromycin (N=61)	Placebo (N=54)	Difference (95% CI)
Oral antibiotic use	7 (11.5)	11 (20.4)	−8.9% (−22.7 to 4.6)
Participants with ≥1 event, n (%)			
Intravenous antibiotic use	3 (4.9)	2 (3.7)	1.2% (−8.2 to 10.2)
Participants with ≥1 event, n (%)			
Inhaled antibiotic use (other than tobramycin)	1 (1.6)	2 (3.7)	−2.1% (−11.0 to 5.5)
Participants with ≥1 event, n (%)			
Pulmonary exacerbation	9 (14.8)	8 (14.8)	−0.1% (−13.7 to 13.0)
Participants with ≥1 event, n (%)			
Hospitalisation	3 (4.9)	3 (5.6)	−0.6% (−10.7 to 8.7)
Participants with ≥1 event, n (%)			

in FEV₁ (95% CI: −2.26 to 6.40) (figure 4). In those able to provide sputum samples for culture, the differences in change in FEV₁ developed almost entirely between week 0 and week 2 before starting inhaled tobramycin (online supplemental figure E5).

The azithromycin group had an average 6-week change from baseline of +0.30 log₁₀ CFU/mL (SD: 1.69 CFU/mL) in *P. aeruginosa* sputum density and the placebo group had an average change of −0.49 log₁₀ CFU/mL (SD: 1.20 CFU/mL). The mean difference between groups in the 6-week change, adjusted for stratification factors, was 0.75 log₁₀ CFU/mL (95% CI: 0.03 to 1.47; p=0.043; figure 3). During the 4-week inhaled tobramycin period, the mean difference in change in log₁₀ CFU/mL *P. aeruginosa* density was 0.64 (95% CI: −0.01 to 1.28; p=0.053). The proportion of participants *P. aeruginosa* positive at each study visit and relative changes in lung function (FEV₁ litres) among the subgroup providing sputum samples are further described in online supplemental table E3 and figures E5 and E6, respectively.

Over 80% of participants reported using chronic azithromycin for ≥30 days at the time of enrolment. This large subpopulation represented common clinical care practice in many countries. Exploratory subgroup analyses were performed to characterise the differences in changes in FEV₁ and *P. aeruginosa* density between treatment groups when considering chronic azithromycin use prior to enrolment (online supplemental table E4, unadjusted data). Those entering the trial using azithromycin and able to produce sputum samples had a difference in the 6-week relative change in FEV₁ of 7.18% (95% CI: 1.05 to 13.32) favouring azithromycin but no difference in the 4-week change during inhaled tobramycin (−0.13%; 95% CI −6.76 to 6.50). Among these participants, the difference in the 6-week change in *P. aeruginosa* density was 1.01 log₁₀ CFU/mL (95% CI: 0.18 to 1.85) favouring placebo and the 4-week change during inhaled tobramycin favouring placebo was 0.71 log₁₀ CFU/mL (95% CI: −0.11 to 1.53). See online supplemental table E4 for additional details, including data from the small group not using azithromycin at enrolment.

Safety

Rates of serious adverse events (SAEs) did not significantly differ between the two treatment groups, 4 participants in the azithromycin group experienced 10 SAEs during the study, while 3 participants in the placebo group experienced 14 SAEs (rate ratio adjusted for follow-up time: 0.67; 95% CI: 0.29 to 1.50).

Fewer total AEs were observed in the azithromycin group during the study, with 109 AEs among 40 participants in the azithromycin group and 136 AEs among 38 participants in the placebo group (rate ratio adjusted for follow-up time: 0.75;

95% CI: 0.58 to 0.97; p=0.026). A large percentage of AEs were attributed to respiratory, thoracic and mediastinal disorders with 22 participants in the azithromycin group experiencing 42 AEs and 30 participants in the placebo group experiencing 74 AEs (online supplemental table E5, rate ratio adjusted for follow-up: 0.53; 95% CI: 0.36 to 0.77). No participants in either treatment group were found to have abnormal QTc intervals measured via ECGs during the study.

DISCUSSION

The TEACH trial was designed to test the impact of using concomitant azithromycin on the clinical response to ongoing inhaled tobramycin, in addition to its impact on *P. aeruginosa* sputum density over a 6-week period. The rationale for this trial emerged from in vitro studies and several post-hoc clinical data analyses suggesting that PwCF using chronic azithromycin may respond less favourably to inhaled tobramycin compared with those not using azithromycin.^{4 5 7–10} In this prospective trial, we hypothesised that the placebo group would be superior to the azithromycin group when testing clinical and microbiological outcomes across a 6-week period that included a 4-week cycle of inhaled tobramycin therapy. We found that placebo-treated participants did not experience greater improvement in FEV₁ or other clinical outcomes. This was despite the fact that placebo-treated participants able to provide sputum samples had greater reduction in *P. aeruginosa* sputum density (ie, bacterial killing) compared with those randomised to azithromycin.

TEACH is one of the few prospective, randomised, placebo-controlled trials to examine the potential for an adverse interaction between proven and widely used therapies in CF. Strengths of the study include the clinical relevance of the tested hypothesis, prospective multicentre conduct with randomisation, blinding with a placebo comparison and a representative participant population. It seems increasingly important to consider whether individual or combined chronic therapies may be less useful than anticipated as the CF community benefits from better overall health and prioritises such research.^{20 21} This not only helps to reduce daily treatment burden by working to identify those therapies that remain effective in long-term use but also opens space to develop new and more effective drugs.

In TEACH, the 6-week change in lung function (FEV₁) was the primary test for clinical benefit and primary outcome of the trial (figure 1). There was a trend toward better FEV₁ in the azithromycin arm compared with placebo. No significant differences occurred among secondary clinical outcomes, including measures of patient-reported respiratory symptom scores, weight or need for additional antibiotics. The azithromycin group experienced statistically fewer AEs, though what this means in the

absence of differences in pulmonary exacerbations or antibiotic use is unclear.

Study outcomes focused on the change over the entire 6 weeks in order to maintain baseline similarities between groups achieved at randomisation (week 0) while enabling wash-in or wash-out of azithromycin for 2 weeks prior to starting inhaled tobramycin. Based on pharmacokinetics data, 2 weeks was identified as sufficiently long to reach very low concentrations of azithromycin in the airway.^{22–25} Some studies find that azithromycin can be measured within leucocytes in the lung beyond 14 days, but the combined clinical and microbiological results from this trial suggest that 2 weeks was adequate to test for the hypothesised interaction with tobramycin as observed *in vitro*.

At enrolment, 80% of participants reported using chronic azithromycin and so relatively few were started on macrolides, while most of those randomised to placebo had macrolide therapy functionally withdrawn. Azithromycin by itself has been shown to improve FEV₁ in CF lung disease, especially in those with *P. aeruginosa* infection.^{27–26} Thus, the small FEV₁ changes during the trial, mostly seen as a decline in FEV₁ in the placebo group, may primarily represent the impact of azithromycin. This interpretation is supported by the fact that much of the change in FEV₁ from baseline occurred over the first 2 weeks after randomisation, which was prior to starting inhaled tobramycin (figure 3; online supplemental table E4).

As a secondary aim, the TEACH trial tested whether those randomised to placebo versus azithromycin would experience greater reduction in *P. aeruginosa* in sputum, which would be consistent with *in vitro* antagonism between these two antibiotics.^{4–6} As theorised, those randomised to placebo had a greater decrease in *P. aeruginosa* sputum density, suggesting greater ability of inhaled tobramycin to kill *P. aeruginosa* in the CF airway if azithromycin is not present (figure 5; online supplemental figure E6). This difference occurred mostly during inhaled tobramycin period (week 2–6). The treatment effect size of 0.75 log₁₀ CFU/mL of sputum is similar in magnitude to the effect of inhaled tobramycin on *P. aeruginosa* sputum density in other trials enrolling participants already using inhaled tobramycin.^{27–30} These microbiological data should be placed in context with the lack of greater clinical benefits (eg, lung function and respiratory symptoms) with placebo and the reduced number of participants able to produce sputum samples for quantitative culture. Modest differences in baseline characteristics and other outcomes measured between those able or unable to provide sputum are provided in online supplemental tables E2, E4.

Additional potential limitation when interpreting study results include the relatively small differences in 6-week and 4-week changes in FEV₁ in both groups, which were variable (online supplemental figure E2) and not statistically significantly different between groups. Changes in lung function should not be overinterpreted beyond the lack of superiority with placebo, a finding that was counter to our hypothesis. However, the 95% CI for the primary outcome of relative change in FEV₁ favouring azithromycin (−0.44 to 7.35) makes it highly unlikely that using azithromycin results in lesser improvement in FEV₁ during continued cycles of inhaled tobramycin. This trial was also not designed or powered for subgroup analyses (eg, prior use of azithromycin), and those results should be viewed as exploratory. Lastly, we enrolled people already using inhaled tobramycin therapy and the study was not designed to determine any impact of azithromycin on the initial response to inhaled tobramycin or long-term effects of chronic therapy (eg, risk of acute pulmonary exacerbation or rate of decline in lung function).

Studies of inhaled antibiotics in CF have reported poor correlation between improved FEV₁ and reduced *P. aeruginosa* sputum

Figure 5 Microbiologic outcomes: (A) mean change from baseline in *Pa* density in log₁₀ CFU/mL and (B) mean *P. aeruginosa* density in log₁₀ CFU/mL. Error bars are 95% CIs. AZM, azithromycin; *Pa*, *Pseudomonas aeruginosa*; TOB, tobramycin.

density when considering individual participants (online supplemental figure E7),^{31–32} but at the level of treatment groups (eg, inhaled antibiotics vs placebo), most studies in PwCF find greater increase in FEV₁ in the group with greater reduction in sputum bacterial density.¹³³ This did not occur in our trial, similar to what has been seen in studies of inhaled levofloxacin in CF and multiple inhaled antibiotics in non-CF bronchiectasis.^{29–34} One potential explanation is that beneficial effects of azithromycin in the airway unrelated to *Pseudomonas* outweighed the effects of increased *P. aeruginosa* burden, resulting in a disconnect between changes in lung function and airway infection.^{35–39} Another potential explanation is that our study population, by design, was not naïve to inhaled tobramycin, and neither group (ie, azithromycin or placebo treated) had a significant increase in FEV₁ during inhaled tobramycin use. A diminishing effect on FEV₁ over subsequent cycles of inhaled tobramycin was reported in even the earliest clinical trials.¹ It would be interesting to conduct this trial in a population with *P. aeruginosa* without prior exposure to inhaled tobramycin and in which larger impacts on FEV₁ may be expected. This was not feasible in the USA but may be possible in other regions where tobramycin use is less common. Our trial, conducted in a population with substantial prior drug exposure, serves to highlight uncertainty about the sustained clinical effect of certain chronic CF medications and how best to measure this. Future research

may need to more directly quantify the health benefits afforded by common daily therapies as more PwCF express interest in reducing burden of care.^{20 21} More specifically, the disconnection between clinical and microbiological outcomes in this trial suggests that better understanding of chronic antimicrobial therapies is needed, in light of treatment burden, cost, potential toxicity and antibiotic stewardship.

Other researchers have reported changes in sputum microbiome during inhaled antibiotics, suggesting that microbiological effects on species other than *P. aeruginosa* may also be important in the clinical response.^{40 41} This is interesting to consider as an alternative explanation for the lack of association between change in *P. aeruginosa* and lung function or other clinical outcomes; however, the investigators reporting microbiome changes similarly found no mean improvement in lung function after 4 weeks of inhaled tobramycin, indicating that the clinical implications of changing sputum microbial ecology through inhaled antibiotics requires further study.⁴⁰

Ultimately, our trial clearly demonstrated that eliminating concomitant azithromycin does not result in greater clinical response to ongoing, chronic inhaled tobramycin over the short term, despite changes in *P. aeruginosa* sputum density that are consistent with antagonism between these two antibiotics in the CF airway. Additional outcomes such as rate of FEV₁ decline, risk of acute pulmonary exacerbations and survival are of great interest but may be increasingly difficult to include in a prospective, randomised study as increasing numbers of PwCF are fortunately experiencing more stable pulmonary health and fewer exacerbations than in the past.^{42 43} Several years ago, inhaled tobramycin use in the US CF patient registry was shown to associate with improved survival.⁴⁴ More recently, analyses of CF patient registries in the USA and France found that inhaled tobramycin and azithromycin each associated with slower rate of decline in FEV₁; however, some of these data also suggest that both medications combined may be less effective.^{7 26 45} The TEACH trial, while reassuring regarding any short-term clinical effects of combined drug use, was not designed to determine such long-term outcomes.

This study represents the first multicentre trial in those with CF chronically infected with *P. aeruginosa* to directly assess clinical and microbiological outcomes associated with the combined use of azithromycin and inhaled tobramycin. While benefit from broad-spectrum antibiotics can extend far beyond antibacterial effects against a specific pathogen, they must be balanced with off-target effects that are complex and often difficult to identify. Like many trials, our findings raise additional questions, including the long-term clinical relevance of microbiological changes in the airway that occur with chronic antibiotic use. As the landscape of CF treatment and care evolves, in particular the expanding use of CFTR modulators, trials similar to TEACH, will be necessary to determine the optimal and least burdensome treatment approaches.

Author affiliations

¹Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA

²Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Centre, Seattle Children's Research Institute, Seattle, Washington, USA

³Department of Microbiology, University of Washington, Seattle, Washington, USA

⁴Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA

⁵Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA

⁶Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Florida Health, Gainesville, Florida, USA

⁷Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA

⁸Department of Pediatrics, Columbia University Medical Center, New York, New York, USA

⁹Department of Medicine, Pulmonary, Allergy and Critical Care Division, University of Minnesota Medical Center, Minneapolis, Minnesota, USA

¹⁰Department of Biostatistics, University of Washington School of Public Health, Seattle, Washington, USA

¹¹Department of Pharmacy, Seattle Children's Hospital, Seattle, Washington, USA

¹²Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA

¹³Department of Medicine, National Jewish Health, Denver, Colorado, USA

Acknowledgements We sincerely thank the participants, study sites, scientific advisory board members and safety monitors who made this study possible.

Collaborators TEACH Study Group includes: Peter Mogayzel, Perry Brown, Gregory Sawicki, Manu Jain, Gary McPhail, Kimberly McBennett, Gary Mueller, Karen Schultz, Susan Millard, Gavin Graff, Clement Ren, Hugo Escobar, Robert Zanni, Thomas Keens, Nicholas Antos, Marie Egan, Patricia Walker, Floyd Livingston, Carlos Milla, Okan Elidemir, Subramanyam Chittivelu, Laurie Varlotta, Joseph Pilewski, Anne Marie Cairns, Kelvin MacDonald, Karen Voter, Fadi Asfour, Douglas Conrad, Christopher Goss, Gary Albers, Jessica Pittman, Ted Kremer, Irene Bondick, Maggie Brassil, Missy Cianciola, Laurel Couture, Jeannette Dingleline, Martha Doyle, Barbra Fogarty, Susan Jacobs, Miya Johnson, Barbara Mathewson, Peter McDonnell, Anna Mead, Matthew Myers and Jill VanDalsen.

Contributors DN, PS, JFC, LS, SLH, JAN and NM-H contributed to the design and initiation of this study. Statistical analysis and advisement was provided by AB, SLH and NM-H. SJM, SK and AK lead critical centralised study activities. DN drafted the manuscript and is responsible for the overall content as guarantor. All authors contributed to the manuscript and read and approved the final manuscript. The TEACH Study Group consists of key study team members at the central coordinating centre and all local investigators who are responsible for ethical board approval, participant recruitment and conduct at local study sites.

Funding This work was supported by the National Institutes of Health (NIH), NHLBI and the Cystic Fibrosis (CF) Foundation. Additional programmatic funding that supported this research was provided by the NIH and NIDDK. NHLBI/NIH organised the independent, external Data Safety Monitoring Board for this study. Beyond that, funding agencies had no role in the design, management, data collection, analyses, or interpretation of the data or in the writing of the manuscript or the decision to submit for publication. The views expressed in this publication are those of the authors and not necessarily those of the NIH or CF Foundation.

Competing interests DN and NM-H, as part of their roles at the Cystic Fibrosis (CF) Foundation Therapeutics Development Network Coordinating Centre, provide consulting to industry sponsors who are developing new drug therapies for cystic fibrosis. Some of these sponsors are working to develop antimicrobial agents. PS and DN report grants from Vertex and Gilead Sciences outside of the published work. RG and GR-B report grants from Vertex outside of the published work. LS reports grants from Merck Co and Bill and Melinda Gates Foundation outside of the published work and payments for Data Safety Monitoring Board or Advisory Boards from Merck Co. Multiple authors have grant support or payments from the CF Foundation.

Patient consent for publication Not applicable.

Ethics approval Ethical approval was obtained at each study site and the coordinating centre from relevant local or national research ethics committees. Written informed consent and assent, when appropriate, to participate were obtained for all study participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. At the time of publication of study findings, accrued data will be made available for sharing with other investigators at academic or non-profit institutions according to NIH data sharing policies (https://grants.nih.gov/grants/policy/data_sharing/). Since original datasets will include sensitive information, including locations and dates of treatment, these data sets will be limited and will omit individual identifiers as per the Federal Health Insurance Portability and Accountability Act (HIPAA). Our foremost concern is protecting the rights and privacy of the persons volunteering to participate in our research studies. Data will be shared upon request with other investigators so long as the request conforms to the purposes specified in the consent form. In our consent form, we have specified that 'the data may be shared with other researchers and used in future research' and that 'the goal of future studies would be to help us understand cystic fibrosis better'. If the purpose intended by the data requestors is not clearly understood as specified in the consent form, the IRB will determine if additional consent is required. Investigators requesting data must sign a data-sharing agreement committing to: (1) using the data only for research purposes and not identifying any individual participant; (2) securing the data using appropriate computer technology; (3) not sharing the data with third parties and (4) destroying

the data after analyses are completed. In addition to sharing the data, we will share a data dictionary, our standard documentation, so that the data will be as usable as practically possible. The Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Centre (CFF TDNCC) Data Archive has a documented process for requesting study data sponsored by the CFF and conducted by the CFF TDNCC. As a part of the process, investigators seeking data will apply, undergo scientific review, provide evidence of IRB approval for their proposed research and submit a data use agreement between their home institution and the TDNCC Data Archive.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

David P Nichols <http://orcid.org/0000-0001-8611-7960>

Sonya L Heltshe <http://orcid.org/0000-0003-2696-2382>

REFERENCES

- Ramsey BW, Pepe MS, Quan JM, *et al*. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis inhaled tobramycin Study Group. *N Engl J Med* 1999;340:23–30.
- Saiman L, Marshall BC, Mayer-Hamblett N, *et al*. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2003;290:1749–56.
- 2019 cystic fibrosis Foundation patient registry annual data report 2019.
- Nichols DP, Happoldt CL, Bratcher PE, *et al*. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. *J Cyst Fibros* 2017;16:358–66.
- Nick JA, Moskowitz SM, Chmiel JF, *et al*. Azithromycin may antagonize inhaled tobramycin when targeting *Pseudomonas aeruginosa* in cystic fibrosis. *Ann Am Thorac Soc* 2014;11:342–50.
- Nichols DP, Caceres S, Caverly L, *et al*. Effects of azithromycin in *Pseudomonas aeruginosa* burn wound infection. *J Surg Res* 2013;183:767–76.
- Nichols DP, Odem-Davis K, Cogen JD, *et al*. Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis. *Am J Respir Crit Care Med* 2020;201:430–7.
- Somayaji R, Russell R, Cogen JD, *et al*. Oral azithromycin use and the recovery of lung function from pulmonary exacerbations treated with intravenous tobramycin or colistimethate in adults with cystic fibrosis. *Ann Am Thorac Soc* 2019;16:853–60.
- Klingel M, Stanojevic S, Tullis E, *et al*. Oral azithromycin and response to pulmonary exacerbations treated with intravenous tobramycin in children with cystic fibrosis. *Ann Am Thorac Soc* 2019;16:861–7.
- Cogen JD, Faino AV, Onchiri F, *et al*. Effect of concomitant azithromycin and tobramycin use on cystic fibrosis pulmonary exacerbation treatment. *Ann Am Thorac Soc* 2021;18:266–72.
- Nichols D, Banes A, Chmiel J. Abstract 283. teach: testing the effects of adding chronic azithromycin to inhaled tobramycin. *Pediatr Pulmonol* 2020;55:S150.
- Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. *Biometrics* 1975;31:103–15.
- Han B, Enas NH, McEntegart D. Randomization by minimization for unbalanced treatment allocation. *Stat Med* 2009;28:3329–46.
- Brown S, Thorpe H, Hawkins K, *et al*. Minimization—reducing predictability for multi-centre trials whilst retaining balance within centre. *Stat Med* 2005;24:3715–27.
- Quanjer PH, Weiner DJ. Interpretative consequences of adopting the global lungs 2012 reference equations for spirometry for children and adolescents. *Pediatr Pulmonol* 2014;49:118–25.
- Mayer-Hamblett N, Retsch-Bogart G, Kloster M, *et al*. Azithromycin for early *Pseudomonas* infection in cystic fibrosis. The optimize randomized trial. *Am J Respir Crit Care Med* 2018;198:1177–87.
- Saiman L, Anstead M, Mayer-Hamblett N, *et al*. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2010;303:1707–15.
- Goss CH, Edwards TC, Ramsey BW, *et al*. Patient-Reported respiratory symptoms in cystic fibrosis. *J Cyst Fibros* 2009;8:245–52.
- Quittner AL, Sawicki GS, McMullen A, *et al*. Psychometric evaluation of the cystic fibrosis Questionnaire-Revised in a national sample. *Qual Life Res* 2012;21:1267–78.
- Gifford AH, Mayer-Hamblett N, Pearson K, *et al*. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy. *J Cyst Fibros* 2020;19:762–7.
- Rowbotham NJ, Smith S, Leighton PA, *et al*. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. *Thorax* 2018;73:388–90.
- Beringer P, Huynh KMT, Kriengkauyiat J, *et al*. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. *Antimicrob Agents Chemother* 2005;49:5013–7.
- Aubert JD, Juillerat-Jeanneret L, Fioroni P, *et al*. Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers. *Pulm Pharmacol Ther* 1998;11:263–9.
- Olsen KM, San Pedro G, Gann LP, *et al*. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. *Antimicrob Agents Chemother* 1996;40:2582–5.
- Sampson MR, Dumitrescu TP, Brouwer KLR, *et al*. Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults. *CPT Pharmacometrics Syst Pharmacol* 2014;3:e103:103.
- Denis A, Touzet S, Diabaté L, *et al*. Quantifying long-term changes in lung function and exacerbations after initiation of azithromycin in cystic fibrosis. *Ann Am Thorac Soc* 2020;17:195–201.
- Konstan MW, Flume PA, Kappler M, *et al*. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. *J Cyst Fibros* 2011;10:54–61.
- Assael BM, Pressler T, Bilton D, *et al*. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. *J Cyst Fibros* 2013;12:130–40.
- Stuart Elborn J, Geller DE, Conrad D, *et al*. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. *J Cyst Fibros* 2015;14:507–14.
- Elborn JS, Vataire A-L, Fukushima A, *et al*. Comparison of inhaled antibiotics for the treatment of chronic *Pseudomonas aeruginosa* lung infection in patients with cystic fibrosis: systematic literature review and network meta-analysis. *Clin Ther* 2016;38:2204–26.
- Mayer-Hamblett N, VanDevanter DR. Accelerated approval or risk reduction? how response biomarkers advance therapeutics through clinical trials in cystic fibrosis. *Trends Mol Med* 2020;26:1068–77.
- VanDevanter DR, Ballmann M, Flume PA. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. *Respir Med* 2011;105 Suppl 2:S18–23.
- McCoy KS, Quittner AL, Oermann CM, *et al*. Inhaled aztreonam lysine for chronic airway *Pseudomonas aeruginosa* in cystic fibrosis. *Am J Respir Crit Care Med* 2008;178:921–8.
- Xu M-J, Dai B. Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis. *Ther Adv Respir Dis* 2020;14:1753466620936866.
- Fujikawa H, Kawakami T, Nakashima R, *et al*. Azithromycin inhibits constitutive airway epithelial sodium channel activation in vitro and modulates downstream pathogenesis in vivo. *Biol Pharm Bull* 2020;43:725–30.
- Vermeersch K, Gabrovska M, Aumann J, *et al*. Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE). A multicenter, randomized, double-blind, placebo-controlled trial. *Am J Respir Crit Care Med* 2019;200:857–68.
- Gibson PG, Yang IA, Upham JW, *et al*. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. *Lancet* 2017;390:659–68.
- Tarran R, Sabater JR, Clarke TC, *et al*. Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. *Am J Physiol Lung Cell Mol Physiol* 2013;304:L746–56.
- Ratjen F, Saiman L, Mayer-Hamblett N, *et al*. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with *Pseudomonas aeruginosa*. *Chest* 2012;142:1259–66.
- Nelson MT, Wolter DJ, Eng A, *et al*. Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome. *Thorax* 2020;75:780–90.
- Heirali A, Thornton C, Acosta N, *et al*. Sputum microbiota in adults with CF associates with response to inhaled tobramycin. *Thorax* 2020;75:1058–64.
- Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, *et al*. Building global development strategies for CF therapeutics during a transitional CFTR modulator era. *J Cyst Fibros* 2020;19:677–87.
- Nichols DP, Durmowicz AG, Field A, *et al*. Developing inhaled antibiotics in cystic fibrosis: current challenges and opportunities. *Ann Am Thorac Soc* 2019;16:534–9.
- Sawicki GS, Signorovitch JE, Zhang J, *et al*. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. *Pediatr Pulmonol* 2012;47:44–52.
- VanDyke RD, McPhail GL, Huang B, *et al*. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis. *Ann Am Thorac Soc* 2013;10:205–12.